Covid-19
AstraZeneca’s Evusheld fails to improve Covid outcomes in Phase III trial
The treatment was found to offer substantial protection by neutralising antibodies against SARS-CoV-2.
The treatment was found to offer substantial protection by neutralising antibodies against SARS-CoV-2.